Mucosal leishmaniasis: the experience of a Brazilian referral center
Abstract INTRODUCTION Pentavalent antimonials (Sbv) are the most commonly used drugs for the treatment of mucosal leishmaniasis (ML), despite their high toxicity and only moderate efficacy. The aim of this study was to report therapeutic responses with different available options for ML. METHODS This study was based on a review of clinical records of 35 patients (24 men and 11 women) treated between 2009 and 2015. RESULTS The median age of patients was 63 years, and the median duration of the disease was 24 months. Seventeen patients received Sbv, while nine patients were treated with liposomal amphotericin B (AmB), and another nine patients were treated with fluconazole. Patients treated with AmB received a total median accumulated dose of 2550mg. The mean duration of azole use was 120 days, and the daily dose ranged from 450 to 900mg. At the three-month follow-up visit, the cure rate was 35%, 67%, and 22% for Sbv, AmB, and azole groups, respectively. At the six-month follow-up visit, the cure rates for Sbv, AmB, and azole groups were 71%, 78%, and 33%, respectively. CONCLUSIONS There is a scarcity of effective ML treatment alternatives, and based on our observations, fluconazole is not a valid treatment option.
Main Authors: | , , , , , , , , |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Sociedade Brasileira de Medicina Tropical - SBMT
2018
|
Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0037-86822018000300318 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
oai:scielo:S0037-86822018000300318 |
---|---|
record_format |
ojs |
spelling |
oai:scielo:S0037-868220180003003182018-12-04Mucosal leishmaniasis: the experience of a Brazilian referral centerPedras,Mariana JunqueiraCarvalho,Janaína de PinaSilva,Rosiana Estéfane daRamalho,Dario BrockSenna,Maria Camilo Ribeiro deMoreira,Hugo Silva AssisMartinho,Lorena Zaine MatosRabello,AnaCota,Gláucia Mucosal leishmaniasis Therapy Meglumine antimoniate Amphotericin B Azole Abstract INTRODUCTION Pentavalent antimonials (Sbv) are the most commonly used drugs for the treatment of mucosal leishmaniasis (ML), despite their high toxicity and only moderate efficacy. The aim of this study was to report therapeutic responses with different available options for ML. METHODS This study was based on a review of clinical records of 35 patients (24 men and 11 women) treated between 2009 and 2015. RESULTS The median age of patients was 63 years, and the median duration of the disease was 24 months. Seventeen patients received Sbv, while nine patients were treated with liposomal amphotericin B (AmB), and another nine patients were treated with fluconazole. Patients treated with AmB received a total median accumulated dose of 2550mg. The mean duration of azole use was 120 days, and the daily dose ranged from 450 to 900mg. At the three-month follow-up visit, the cure rate was 35%, 67%, and 22% for Sbv, AmB, and azole groups, respectively. At the six-month follow-up visit, the cure rates for Sbv, AmB, and azole groups were 71%, 78%, and 33%, respectively. CONCLUSIONS There is a scarcity of effective ML treatment alternatives, and based on our observations, fluconazole is not a valid treatment option.info:eu-repo/semantics/openAccessSociedade Brasileira de Medicina Tropical - SBMTRevista da Sociedade Brasileira de Medicina Tropical v.51 n.3 20182018-06-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0037-86822018000300318en10.1590/0037-8682-0478-2017 |
institution |
SCIELO |
collection |
OJS |
country |
Brasil |
countrycode |
BR |
component |
Revista |
access |
En linea |
databasecode |
rev-scielo-br |
tag |
revista |
region |
America del Sur |
libraryname |
SciELO |
language |
English |
format |
Digital |
author |
Pedras,Mariana Junqueira Carvalho,Janaína de Pina Silva,Rosiana Estéfane da Ramalho,Dario Brock Senna,Maria Camilo Ribeiro de Moreira,Hugo Silva Assis Martinho,Lorena Zaine Matos Rabello,Ana Cota,Gláucia |
spellingShingle |
Pedras,Mariana Junqueira Carvalho,Janaína de Pina Silva,Rosiana Estéfane da Ramalho,Dario Brock Senna,Maria Camilo Ribeiro de Moreira,Hugo Silva Assis Martinho,Lorena Zaine Matos Rabello,Ana Cota,Gláucia Mucosal leishmaniasis: the experience of a Brazilian referral center |
author_facet |
Pedras,Mariana Junqueira Carvalho,Janaína de Pina Silva,Rosiana Estéfane da Ramalho,Dario Brock Senna,Maria Camilo Ribeiro de Moreira,Hugo Silva Assis Martinho,Lorena Zaine Matos Rabello,Ana Cota,Gláucia |
author_sort |
Pedras,Mariana Junqueira |
title |
Mucosal leishmaniasis: the experience of a Brazilian referral center |
title_short |
Mucosal leishmaniasis: the experience of a Brazilian referral center |
title_full |
Mucosal leishmaniasis: the experience of a Brazilian referral center |
title_fullStr |
Mucosal leishmaniasis: the experience of a Brazilian referral center |
title_full_unstemmed |
Mucosal leishmaniasis: the experience of a Brazilian referral center |
title_sort |
mucosal leishmaniasis: the experience of a brazilian referral center |
description |
Abstract INTRODUCTION Pentavalent antimonials (Sbv) are the most commonly used drugs for the treatment of mucosal leishmaniasis (ML), despite their high toxicity and only moderate efficacy. The aim of this study was to report therapeutic responses with different available options for ML. METHODS This study was based on a review of clinical records of 35 patients (24 men and 11 women) treated between 2009 and 2015. RESULTS The median age of patients was 63 years, and the median duration of the disease was 24 months. Seventeen patients received Sbv, while nine patients were treated with liposomal amphotericin B (AmB), and another nine patients were treated with fluconazole. Patients treated with AmB received a total median accumulated dose of 2550mg. The mean duration of azole use was 120 days, and the daily dose ranged from 450 to 900mg. At the three-month follow-up visit, the cure rate was 35%, 67%, and 22% for Sbv, AmB, and azole groups, respectively. At the six-month follow-up visit, the cure rates for Sbv, AmB, and azole groups were 71%, 78%, and 33%, respectively. CONCLUSIONS There is a scarcity of effective ML treatment alternatives, and based on our observations, fluconazole is not a valid treatment option. |
publisher |
Sociedade Brasileira de Medicina Tropical - SBMT |
publishDate |
2018 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0037-86822018000300318 |
work_keys_str_mv |
AT pedrasmarianajunqueira mucosalleishmaniasistheexperienceofabrazilianreferralcenter AT carvalhojanainadepina mucosalleishmaniasistheexperienceofabrazilianreferralcenter AT silvarosianaestefaneda mucosalleishmaniasistheexperienceofabrazilianreferralcenter AT ramalhodariobrock mucosalleishmaniasistheexperienceofabrazilianreferralcenter AT sennamariacamiloribeirode mucosalleishmaniasistheexperienceofabrazilianreferralcenter AT moreirahugosilvaassis mucosalleishmaniasistheexperienceofabrazilianreferralcenter AT martinholorenazainematos mucosalleishmaniasistheexperienceofabrazilianreferralcenter AT rabelloana mucosalleishmaniasistheexperienceofabrazilianreferralcenter AT cotaglaucia mucosalleishmaniasistheexperienceofabrazilianreferralcenter |
_version_ |
1756380625698291712 |